Clinical Trial Update: A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing safety and efficacy of a gastric-retentive formulation (AP-CD/LD) in advanced Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• AP-CD/LD

Snippet

Sponsor: Intec Pharma Ltd. | Conditions: Parkinson's Disease | Phase 3 | Status: UNKNOWN